Scroll for more



Barbara A. Munder
Director, Board of Directors


Ms. Munder became a Director for Sucampo in February 2013. She currently serves as Senior Advisor at Institutional Investor LLC, an international business-to-business publisher. She previously served as Executive Director of The Hedge Fund Institutional Forum at Institutional Investor LLC until 2005 and was a principal of Munder & Associates, a marketing and web-strategy consulting firm, from 2001 to 2002. Also in 2001, Ms. Munder served as Chief Operating Officer at Womenfuture LLC, a distance learning company, where she oversaw e-business strategy. From 1994 to 2000, Ms. Munder held various positions with The McGraw-Hill Companies, Inc., including Senior Vice President of New Initiatives, overseeing corporate-wide electronic commerce, and Senior Vice President of Corporate Affairs, responsible for branding, marketing, communications and Washington affairs.

Ms. Munder currently serves as a Director for Munder Realty Corporation, a private real estate firm. Previously, she served as a Director for PetSmart Inc.  She has been on the advisory board for DOAR, a private litigation information services and consulting firm, Izzo Systems, a manufacturer of ergonomically designed golf bags and straps, and Lighthouse International, a non-profit for the visually impaired.

Ms. Munder earned a bachelor’s degree in political science from Elmira College and a master’s degree in business administration with a concentration in finance from Stern School of Business Administration at New York University.

Contact Us
Tel: +1-301-961-3400

Sucampo Pharmaceuticals, Inc. is focused on the development and commercialization of specialized medicines that meet major unmet medical needs of patients worldwide. Sucampo has two marketed products – AMITIZA, its lead product, and RESCULA – and a late-stage pipeline of product candidates in clinical development for orphan disease areas. VTS-270 is a mixture of 2-hydroxypropyl-B-cyclodextrins with a specific compositional fingerprint that has been granted orphan designation in the U.S. and Europe and is in a pivotal Phase 2/3 clinical trial for the treatment of Niemann-Pick Disease Type C-1. Sucampo has an option for the North American rights to CPP1- x/sulindac, which is in Phase 3 development for the treatment of familial adenomatous polyposis and has been granted orphan drug designation in the U.S. A global company, Sucampo is headquartered in Rockville, Maryland, and has operations in Japan and Switzerland.